Latest News

(UroToday.com) In this presentation, Dr. Garcia del Muro presented data from the IMMUNOPRESERVE-SOGUG trial, which aimed to test combined immunotherapy with durvalumab and tremelimumab and radiotherapy as a chemotherapy-free strategy for bladder preservation in muscle invasive bladder cancer (MIBC). The rationale for this approach is based on (1) immunotherapy has significant activity in the neoadjuvant […]

(UroToday.com) Overall survival (OS) is widely accepted as the most relevant outcome for the assessment of cancer-directed treatments. However, in prostate cancer, the natural history may be protracted and, as such, there has been considerable interest in identifying surrogate outcomes which may be more rapidly assessed. Radiographic progression-free survival (rPFS) is one such potential surrogate […]

(UroToday.com) It would be hard to overstate the effect the COVID-19 pandemic has had on life in Western nations. In addition to dramatic changes in day-to-day life, stay-at-home orders, mandates for social distancing, and efforts to reduce health care utilization resulted in significant changes in the practice of medicine. In the Prostate, Testicular, Penile Poster session […]

(UroToday.com) Disparities in prostate cancer incidence and outcomes between African American and Caucasian men in the United States have been well documented. While many of the differences in outcomes are attributable to health system disparities (as evidence by equivalent outcomes when patients are treated in equal access models), emerging data suggest potential differences in the tumor […]

(UroToday.com) As part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, during the session entitled “Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?” Dr. Bradley Carthon discussed prostate cancer as a case study in disparities within cancer care.

Adenosine triphosphate (ATP) is that all-important organic compound that we first learn about in biology class back in secondary school, and we revisit countless times in our college and medical school biochemistry courses.  It is found in all known forms of life, is utilized for intracellular energy transfer, and is often loosely referred to as […]

{{header-clinical-trials-navigation}} A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors Condition: Neoplasms Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT02723955 Sponsor: GlaxoSmithKline Phase: Phase 1 Eligibility: Age: minimum 18 Years maximum N/A Gender: All Inclusion Criteria: Capable of giving signed, […]

The recent randomized controlled phase III CLEAR trial results are the last to complement immune checkpoint inhibitor (ICI)-based doublet combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma.

To explore the prognostic role of the controlling nutritional status score in patients with metastatic renal cell carcinoma. We retrospectively analyzed 107 patients with metastatic renal cell carcinoma who received their diagnosis between 2007 and 2018 and were treated with or without a first-line interferon or tyrosine kinase inhibitor at a single cancer center.

The aim of the study was to evaluate the feasibility of utilizing peripheral androgen blockade in men with biochemical recurrent castrate-sensitive prostate cancer. A registration study to track outcomes of men with biochemical recurrent castrate-sensitive prostate cancer treated with peripheral androgen blockade utilizing concomitant administration of finasteride and bicalutamide.